4 min read
THE TRUMP ADMINISTRATION has not been shy about its pro-peptide stance. US Health and Human Services Secretary Robert F. Kennedy Jr. has pushed to make six popular yet unapproved peptides available for compounding to people with a prescription. A recent FDA advisory committee meeting voted in favor of adding six out of seven peptides to a list of substances that U.S. compounding pharmacies are allowed to manufacture and supply.
Six out of seven. So what happened to that last peptide? Emideltide, also dubbed DSIP, is a peptide people have turned to for better sleep. And it was the only peptide the FDA advisory board voted against moving out of the Category 2 list—a substance considered to carry significant safety risks, with compounding pharmacies prohibited from making it. Here’s why.
What Is Emideltide and What Is It Supposed to Do?
EMIDELTIDE IS A nine-amino-acid peptide originally isolated from the blood of sleeping rabbits during electrically induced sleep in the late 1970s.…